“Efficacy and Safety of Risankizumab Compared With Apremilast in Patients With Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s257, https://doi.org/10.25251/skin.7.supp.257.